Drug Approval | January 03, 2024
Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
The company has received five final approvals
The company has received five final approvals
Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
The product will be manufactured at Lupin's Pithampur facility in India
Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD
Varenicline Tablets, 0.5 mg and 1 mg are indicated for use as an aid to smoking cessation treatment.
This product will be manufactured by Indoco Remedies at their manufacturing facility located at Goa
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
Subscribe To Our Newsletter & Stay Updated
